A biotech company tries to retrofit a lung drug to prevent Covid-19’s after effects

This post was originally published on this site

As the world scrambles to find antiviral treatments and vaccines for the novel coronavirus, some scientists are looking ahead to a problem on the horizon: Many Covid-19 survivors will have long-term lung injuries, and medicine has little to offer them.

Click here to read full article